Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 2/20 | 0.40 |
| ▸ | ALPI | P09923 | 2/20 | 0.40 |
| ▸ | ALPG | P10696 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724667 | 0.90 | KMT2A (0.41) | HTR2CHRH3L3MBTL1ALDH1A1RAB9A | |
| SCHEMBL5724025 | 0.90 | KMT2A (0.43) | HTR2CHRH3L3MBTL1ALDH1A1RAB9A | |
| SCHEMBL5724457 | 0.89 | KMT2A (0.45) | HTR2CHRH3L3MBTL1ALDH1A1RAB9A | |
| SCHEMBL5724532 | 0.88 | TSHR (0.40) | HRH3ALDH1A1RAB9A | |
| SCHEMBL5724396 | 0.88 | HRH3 (0.37) | HTR2CHRH3L3MBTL1RAB9A | |
| SCHEMBL5724538 | 0.84 | HRH3 (0.37) | HRH3L3MBTL1 | |
| SCHEMBL5724039 | 0.84 | HTR2C (0.50) | HTR2CHRH3L3MBTL1ALDH1A1RAB9A | |
| SCHEMBL5723657 | 0.80 | HRH3 (0.47) | HRH3L3MBTL1ALDH1A1RAB9A | |
| SCHEMBL5723664 | 0.79 | HRH3 (0.40) | HTR2CHRH3L3MBTL1ALDH1A1RAB9A | |
| SCHEMBL5724259 | 0.78 | OGA (0.41) | HRH3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1289498-C | 1-methylcarbapenem derivatives | SANKYO CO (JP) | 2006-12-13 | — | — | CN | disclosed |
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| CN-1486317-A | 1-methylcarbapenem derivatives | ������������ʽ���� | 2004-03-31 | — | — | CN | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | HTR2C 4623/4885HRH3 3678/4885ALPL 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.